Company Overview
More
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals dedicated to the discovery or licensing, development and commercialization of proprietary therapies to address a large number of unmet medical needs in the Chinese market, including oncology, autoimmunity and infectious diseases. The company has a range of patent candidates from the discovery phase to the later stages of the clinical program. It includes Niraparib (ZL-2306), ZL-2103, ZL-1101 and so on.
CEO： Ying Du
Market： Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
09688 ZAI LAB-SB
26.750-1.250-4.46%
Market Close 05/25 16:08 CCT
High
27.450
Open
26.000
Turnover
16.73M
Low
26.000
Pre Close
28.000
Volume
621.91K
Price Forecast
No Data
News
Comment
ZAI LAB-SB: ANNOUNCEMENT OF THE 2022 Q1 FINANCIAL RESULTS
ZAI LAB-SB: NOTICE OF BOARD ACTION AND DATE OF PUBLICATION OF FIRST QUARTER 2022 RESULTS ANNOUNCEMENT
ZAI LAB-SB: 2021 ANNUAL REPORT
ZAI LAB-SB: ANNOUNCEMENT OF THE 2021 FISCAL YEAR FINANCIAL RESULTS
ZAI LAB-SB: NOTICE OF BOARD ACTION AND DATE OF PUBLICATION OF FISCAL YEAR 2021 RESULTS ANNOUNCEMENT
ZAI LAB-SB: ANNOUNCEMENT OF THE 2021 Q3 FINANCIAL RESULTS
ZAI LAB-SB: NOTICE OF BOARD ACTION AND DATE OF PUBLICATION OF THIRD QUARTER 2021 RESULTS ANNOUNCEMENT
ZAI LAB-SB: 2021 INTERIM REPORT
ZAI LAB-SB: ANNOUNCEMENT OF THE 2021 INTERIM FINANCIAL RESULTS
ZAI LAB-SB: NOTICE OF BOARD ACTION AND DATE OF PUBLICATION OF 2021 INTERIM RESULTS ANNOUNCEMENT